K Pharma

K Pharma EBIT per Employee

The EBIT per Employee of K Pharma (4896.T) as of Oct 19, 2026 is -70.47 M JPY. In the previous year, EBIT per Employee was -64.33 M JPY — a change of 9.53% (lower).

EBIT per Employee

-70.47 MJPY

YoY

9.53%

Last updated:

EBIT per Employee of K Pharma is 2025 -70.47 M JPY. EBIT per Employee of K Pharma was 2024 -64.33 M JPY. It decreases by 9.53% lower compared to the previous year.

The K Pharma EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2021
-16.88 M JPY
Jan 1, 2022
-27.21 M JPY
Jan 1, 2023
28.16 M JPY
Jan 1, 2024
-64.33 M JPY
Jan 1, 2025
-70.47 M JPY
The K Pharma EBIT per Employee history
YEAREBIT per EmployeeYoY
-70.47 MJPY+9.53%
-64.33 MJPY-328.47%
28.16 MJPY-203.47%
-27.21 MJPY+61.18%
-16.88 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

K Pharma Stock analysis

What does K Pharma do? K Pharma Inc is a Japan-based pharmaceutical company headquartered in Minato-ku, Tokyo. The company operates in the Health Care sector, specifically within the Pharmaceuticals industry. It has a small team of 13 full-time employees. K Pharma Inc completed its initial public offering (IPO) on October 17, 2023, with the ticker symbol 4896.T and ISIN JP3280900006. The company's website is https://kpharma.co.jp/. K Pharma Inc focuses on the research, development, manufacture, and sale of pharmaceuticals. It is engaged in the field of induced pluripotent stem cell (iPS) drug discovery, which involves creating neural progenitor cells from iPS cells. These cells are cryopreserved and used in a treatment process where 200,000 cells are transplanted via injection into the spinal cord injury site of patients. The company also conducts research, development, manufacture, and sale of regenerative medicine products. K Pharma Inc operates through a single business segment, concentrating on pharmaceutical and regenerative medicine solutions. The company's activities are centered on developing innovative treatments, particularly in the area of spinal cord injury recovery using stem cell technology. K Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about K Pharma stock

EBIT per Employee of K Pharma is -70.47 M JPY in 2025.

EBIT per Employee of K Pharma changed from -64.33 M JPY to -70.47 M JPY, representing a 9.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee K Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's K Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — K Pharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — K Pharma